A novel protein regulator of tumor angiogenesis, TMEM230, was recently characterized by researchers to have a role in tumor development and vascularization, with potential as a target for anti-tumor therapy in difficult-to-treat cancers such as glioblastoma.
A 'new technology shows promise by analyzing images of suspicious-looking lesions and quickly producing a detailed, microscopic image of the skin, bypassing several standard steps typically used for diagnosis - including skin biopsy, tissue fixation, processing, sectioning and histochemical staining.
Mass spectrometry – a powerful tool for analysing the molecular composition of a tissue sample – is invaluable during cancer surgery. However, mass spectrometers are complex and unwieldy, and certainly a poor fit for an operating room (OR). To create a bridge between the lab and OR, Professor Livia S Eberlin, from Baylor College of Medicine, has developed a very special ‘pen’.
A new approach to ‘prime’ the tumour environment may improve how effective chemotherapy is for pancreatic ductal adenocarcinoma, one of the most aggressive forms of pancreatic cancer. In preclinical models, a team at the Garvan Institute of Medical Research could enhance the tumours’ response to chemotherapy by reducing the stiffness and density of the connective tissue known as the stroma,…
Research led by the Queensland University of Technology (QUT) on the interaction between prostate cancer cells and the tumour microenvironment has shed more light on the propensity of some types of prostate cancer to metastasize to bone more readily than other types.
Classic antidepressants could help improve modern cancer treatments. They slowed the growth of pancreatic and colon cancers in mice, and when combined with immunotherapy, they even stopped the cancer growth long-term. In some cases the tumors disappeared completely, researchers at the University of Zurich (UZH) and University Hospital Zurich (USZ) have found. Their findings will now be tested in…
A new technology that can study which therapies will work on patients with solid cancerous tumours has been developed by scientists at University College London (UCL). Researchers say the tool, which can rapidly test tumorous tissue against different treatments, such as chemotherapy, immunotherapy or radiotherapy, could be used by clinicians to pinpoint the best therapy for a particular patient.
Scientists from the German Cancer Research Center (DKFZ) and the Medical Faculty Mannheim, Heidelberg University, have identified a new growth factor produced by blood vessels that enables tumor cells to metastatically colonize organs.
A new study from the University of Helsinki shows that cells that are freshly isolated from lung cancers can be used to create robust drug response data. This approach can identify actionable or non-responsive treatments, illustrated by a case study in which the assay was used to guide the compassionate treatment of a patient.
For the first time, researchers at the Norwegian University of Science and Technology (NTNU) have shown how cancer cells reprogram themselves to produce lactic acid and to tolerate the acidic environment that exists around tumors. The finding could lead to a whole new direction for treating cancer. The breakthrough is the result of more than 13 years of work. The next step in research could…
A novel therapy engineered by Northwestern Medicine investigators improved progression-free and overall survival for patients with newly diagnosed malignant gliomas, according to results from a recent phase I clinical trial.
El laboratorio de Genómica Biomédica del IRB Barcelona (Institute for Research in Biomedicine) ha desarrollado un método computacional que identifica las mutaciones causantes del cáncer para cada tipo de tumor.
The Biomedical Genomics laboratory at the Institute for Research in Biomedicine (IRB) Barcelona has developed a computational tool that identifies cancer driver mutations for each tumour type. This and other developments produced by the same lab seek to accelerate cancer research and provide tools to help oncologists choose the best treatment for each patient. The study has been published in the…
Miniature tumours in the lab are able to predict whether the corresponding real-life patients will benefit from immunotherapy. “We’ve solved a major problem many scientists had been facing: preserving a tumours original composition and structure outside of the patient in the lab”, says cancer researcher Daniela Thommen.
Uppsala University scientists have designed a new mouse model that facilitates study of factors contributing to the progression of human bladder cancer and of immune-system activation when the tumour is growing. Using this model, they have been able to study how proteins change before, while and after a tumour develops in the bladder wall. The study has now been published in the scientific…
In a collaboration with the Faculty of Statistics at TU Dortmund and the University Medical Center in Mainz, a research team at the Leibniz Research Centre for Working Environment and Human Factors in Dortmund (IfADo) has developed a test that can be used to predict the success of therapy for breast cancer. Breast cancer is one of the most common tumour diseases worldwide. One in eight women will…
The EU-funded consortium Laser and Ultrasound Co-analyzer for Thyroid Nodules (LUCA) has developed a non-invasive, low-cost device that brings a new solution for thyroid cancer screening.
Scientists at the University College London (UCL) have made a ‘surprising’ discovery that glioblastoma, an aggressive brain cancer, mimics normal brain repair in white matter, which leads to the tumour becoming less malignant. In the study on mice, funded by Cancer Research UK and published in Nature Communications, researchers used these novel findings to identify drugs which could be used,…
Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors.…
Lung tumors are home to immune cells that affect their growth and resistance to treatment. Looking at neutrophils, scientists led by EPFL have discovered that the key might lie in the cells’ ability to metabolize glucose, opening an entirely new target for improving radiotherapy.
Healthy and cancer cells can look similar under a microscope. One way of differentiating them is by examining the level of acidity, or pH level, inside the cells. Tapping on this distinguishing characteristic, a research team from the National University of Singapore (NUS) has developed a technique that uses artificial intelligence (AI) to determine whether a single cell is healthy or cancerous…
Do BMMFs, the novel infectious agents found in dairy products and bovine sera, play a role in the development of colorectal cancer? Scientists led by Harald zur Hausen detected the pathogens in colorectal cancer patients in close proximity to tumors. The researchers show that the BMMFs trigger local chronic inflammation, which can cause mutations via activated oxygen molecules and thus promote…
BOLD-100/KP1339 is a ruthenium-based anticancer agent that has been co-developed at the University of Vienna and which has shown promising results in clinical trials in cancer patients. However, the mode of action of this metal compound has not yet been fully elucidated. Researchers from the University of Vienna and the Medical University of Vienna have now been able to demonstrate that BOLD-100…
Tumour metabolism can be imaged with MRI as a technique to help determine cancer aggressiveness and response to therapy. The work by a UK-based group, on probing cancer metabolism non-invasively with clinical hyperpolarised carbon-13 MRI, can detect metabolic changes in the tumour. As metabolic changes occur much earlier than change in tumour size, this could have implications for quicker…
An international research group led by the University of Basel has developed a promising strategy for therapeutic cancer vaccines. Using two different viruses as vehicles, they administered specific tumor components in experiments on mice with cancer in order to stimulate their immune system to attack the tumor. The approach is now being tested in clinical studies.